HGNC Approved Gene Symbol: PATE1
Cytogenetic location: 11q24.2 Genomic coordinates (GRCh38) : 11:125,746,279-125,749,867 (from NCBI)
To identify target antigens for prostate cancer therapy, Bera et al. (2002) combined screening of the EST database and experimental expression analysis to identify genes expressed in normal prostate and prostate cancer but not in essential human tissues. Using this approach, they identified the PATE gene, which is expressed specifically in prostate cancer, normal prostate, and testis. The cysteine-rich PATE protein contains 127 amino acids, including a phospholipase A2 motif (see 172411) at its C terminus, and has a molecular mass of 14 kD. The amino acid sequence of PATE shows structural similarities to a group of proteins known as 3-finger toxins, which includes the extracellular domain of the type I transforming growth factor-beta receptor (TGFBR1; 190181). Northern blot analysis detected a 1.5-kb transcript in prostate and testis. In situ hybridization showed that PATE mRNA is expressed in the epithelial cells of prostate cancers and in normal prostate. Cell fractionation analysis revealed that the PATE protein is localized in the membrane fraction of the cell. Bera et al. (2002) concluded that the restricted expression of PATE makes it a potential candidate for immunotherapy of prostate cancer.
By genomic sequence analysis, Bera et al. (2002) determined that the PATE gene contains 5 exons and spans 3.5 kb. Promoter analysis identified a TATA box and 3 potential androgen response elements.
By genomic sequence analysis, Bera et al. (2002) mapped the PATE gene to chromosome 11q24.
Bera, T. K., Maitra, R., Iavarone, C., Salvatore, G., Kumar, V., Vincent, J. J., Sathyanarayana, B. K., Duray, P., Lee, B. K., Pastan, I. PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach. Proc. Nat. Acad. Sci. 99: 3058-3063, 2002. [PubMed: 11880645] [Full Text: https://doi.org/10.1073/pnas.052713699]